Dr. Nishi Suryavanshi Receives Award from ACTG Network

Date: 01/07/2022

Congratulations, Nishi Suryavanshi, recipient of ACTG’s Tuberculosis Transformative Science Group Special Contributions Award.

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...